Denis Gravel
Directeur/Bestuurslid bij Transdiff, Inc.
Profiel
Denis Gravel is the founder of Enobia Pharma, Inc. which was founded in 1997.
Currently, he holds the position of Director at Transdiff, Inc. and Centre de Transmission J.D.H., Inc.
Actieve functies van Denis Gravel
| Bedrijven | Functie | Begin |
|---|---|---|
Transdiff, Inc.
 Transdiff, Inc. Specialty StoresRetail Trade Transdiff, Inc. provides truck dealership services. Its services include transmission, differential, engine, drive shaft, parts, mechanical service, and sale of new and used trucks. The company is headquartered in Quebec, Canada. | Directeur/Bestuurslid | - |
Centre de Transmission J.D.H., Inc.
 Centre de Transmission J.D.H., Inc. Wholesale DistributorsDistribution Services Centre de Transmission J.D.H., Inc. engages in the sale of new trucks and Peterbilt parts and services. The company was founded in 1976 and is headquartered in Quebec, Canada. | Directeur/Bestuurslid | - |
Eerdere bekende functies van Denis Gravel
| Bedrijven | Functie | Einde |
|---|---|---|
Enobia Pharma, Inc.
 Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | Oprichter | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 3 |
|---|---|
Enobia Pharma, Inc.
Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | Health Technology |
Transdiff, Inc.
Transdiff, Inc. Specialty StoresRetail Trade Transdiff, Inc. provides truck dealership services. Its services include transmission, differential, engine, drive shaft, parts, mechanical service, and sale of new and used trucks. The company is headquartered in Quebec, Canada. | Retail Trade |
Centre de Transmission J.D.H., Inc.
Centre de Transmission J.D.H., Inc. Wholesale DistributorsDistribution Services Centre de Transmission J.D.H., Inc. engages in the sale of new trucks and Peterbilt parts and services. The company was founded in 1976 and is headquartered in Quebec, Canada. | Distribution Services |
